A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

被引：0

作者：

Donghoon Shin

Yoon Jung Lee

Jihye Choi

Dahyoung Lee

Minjeong Park

Magdalena Petkova

机构：

[1] Samsung Bioepis Co.,Medical Affairs

[2] Ltd,Clinical Development

[3] Samsung Bioepis Co.,Biometrics

[4] Ltd,Clinical Bioanalysis

[5] Samsung Bioepis Co.,Clinical Pharmacology Unit

[6] Ltd,undefined

[7] Samsung Bioepis Co.,undefined

[8] Ltd,undefined

[9] SGS LSS,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2020年 / 86卷

关键词：

SB8; Bevacizumab; Biosimilar; Pharmacokinetics; Immunogenicity;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：567 / 575

页数：8

共 50 条

[41] A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men
Inderjeet Singh
Ronak Patel
Akash Patel
Vinu Jose
Cancer Chemotherapy and Pharmacology, 2020, 86 : 193 - 202
[42] Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers
Lissy, Michael
Stiff, Dwight D.
Kowalski, Mark M.
Moore, Keith A.
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (10) : 2423 - 2428
[43] A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra(R)) in Chinese healthy subjects
Zhang, Hong
Li, Xiaojiao
Liu, Jingrui
Li, Cuiyun
Wu, Min
Zhu, Xiaoxue
Sun, Jixuan
Fang, Min
Ding, Yanhua
ANNALS OF MEDICINE, 2021, 53 (01) : 375 - 383
[44] A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01)
Yin, Donghua
Barker, Kerry B.
Li, Ruifeng
Meng, Xu
Reich, Steven D.
Ricart, Alejandro D.
Rudin, Dan
Taylor, Carrie T.
Zacharchuk, Charles M.
Hansson, Arne G.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (06) : 1281 - 1290
[45] A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects
Zhang, Hong
Wu, Min
Zhu, Xiaoxue
Li, Cuiyun
Li, Xiaojiao
Sun, Jixuan
Liu, Chengjiao
Liu, Quan
Wei, Wei
Niu, Junqi
Ding, Yanhua
FRONTIERS IN PHARMACOLOGY, 2020, 11
[46] A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment
Bramson, C
Ouellet, D
Roman, D
Randinitis, E
Gardner, MJ
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01) : 29 - 36
[47] A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers
Wang, Yanli
Gao, Zhenyue
Liu, Zhengzhi
Liu, Guangwen
Qu, Xinyao
Chen, Jiahui
Ren, Xinran
Xu, Zhongnan
Yang, Haimiao
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (02) : 225 - 234
[48] A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar
Wang, Yanli
Liu, Zhengzhi
Deng, Qiaohuan
Su, Zhengjie
Xue, Jinling
Zhao, Yicheng
Yang, Haimiao
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (11) : 849 - 855
[49] A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects
Lee, Hyun A.
Jang, Hyerin
Jeong, Deokyoon
Kim, Younsoo
Fuhr, Rainard
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022, 60 (06) : 269 - 279
[50] Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects
Qian, Hongjie
Wu, Xue
Chen, Qian
Li, Tingting
Wang, Wei
Jia, Jingying
Yu, Chen
Li, Ke
Sai, Yang
Su, Weiguo
Liu, Yanmei
CLINICAL THERAPEUTICS, 2020, 42 (09) : 1778 - 1786

← 1 2 3 4 5 →